ClinicalTrials.Veeva
Menu

Find clinical trials for Heart Disease in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Heart Diseases
Coronary Artery Disease
Cardiovascular Diseases
Heart Failure
Myocardial Ischemia
Coronary Disease
Kidney Diseases

Heart Disease trials near Valencia, VC, ESP:

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (Re-PHIRE)

is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart...

Enrolling
Heart Failure
Pulmonary Hypertension (World Health Organization Group 2)
Drug: AZD3427
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Valencia, Spain and 64 other locations

tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease...

Enrolling
Ischemic Heart Disease
Coronary Artery Disease
Other: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Fundación EPIC

Valencia, Spain and 44 other locations

Locations recently updated

with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Valencia, Spain and 191 other locations

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with...

Enrolling
Persistent Atrial Fibrillation
Device: FARAPULSE™ Pulsed Field Ablation (PFA) System
Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific
Boston Scientific

Valencia, Spain and 72 other locations

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Phase 3

Amgen
Amgen

Valencia, Comunidad Valenciana, Spain and 851 other locations

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Phase 3

Novo Nordisk
Novo Nordisk

Valencia, Spain and 588 other locations

cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

València, Valencia, Spain and 617 other locations

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. ...

Enrolling
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Ziltivekimab
Drug: Placebo

Phase 3

Novo Nordisk
Novo Nordisk

Valencia, Spain and 735 other locations

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

Phase 3

Amgen
Amgen

Valencia, Comunidad Valenciana, Spain and 736 other locations

Rationale:Permanent cardiac pacing is the only available therapy in patients with atrioventricular (AV) conduction disorders and can be life...

Enrolling
Cardiac Pacing
Left Ventricular Septal Pacing
Procedure: Left ventricular septal pacing
Procedure: Right ventricular pacing
Maastricht University

Valencia, Spain and 12 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems